SARON Trial Finds Radiotherapy Boosts Progression-Free Survival in Oligometastatic Lung Cancer

For patients whose lung cancer has spread to only a few distant sites, the standard approach relies heavily on systemic therapies like chemotherapy and immunotherapy. But a new randomized trial suggests that aggressively targeting those visible tumors with radiation can keep the disease at bay significantly longer.[4][5]

The findings come from the SARON trial, presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid. Researchers found that adding local consolidation radiotherapy to standard systemic treatment increased progression-free survival by 56 percent in patients with synchronous oligometastatic non-small cell lung cancer.[4][5]

Oligometastatic disease represents a unique intermediate state in cancer progression. Rather than spreading widely throughout the body, the cancer has migrated to a limited number of secondary locations—typically defined as one to five metastases across three or fewer organs—at the time of the initial diagnosis.[1][4]

Because the disease has already escaped the lungs, oncologists traditionally rely on whole-body systemic treatments to chase down microscopic cancer cells. However, macroscopic tumors often develop resistance to these drugs, eventually serving as the origin points for further aggressive spread.[6]

Ablating Visible Tumors

The SARON trial was designed to test whether physically destroying those visible tumors could alter the disease's trajectory. Sponsored by University College London and funded by Cancer Research UK, the Phase 2 study enrolled 140 patients across 19 clinical centers in the United Kingdom.[1][4]

Participants were randomized equally into two treatment arms. The control group received the standard of care, consisting of systemic chemotherapy, immunotherapy, or a combination of both. The experimental group received the same systemic backbone, followed by high-dose local consolidation radiotherapy.[4]

This radiation was directed at all known sites of disease, including the primary lung tumor, affected nearby lymph nodes, and the distant secondary metastases. Where appropriate, clinicians utilized stereotactic ablative radiotherapy, a highly precise technique that delivers intense radiation doses to well-defined targets while sparing surrounding healthy tissue.[4][5]

"Until now, there has been limited randomised evidence about the benefits of adding radiotherapy to the standard of care systemic treatment for patients with oligometastatic non-small cell lung cancer," said Dr. Fiona McDonald, chief investigator of the SARON trial and a consultant thoracic clinical oncologist at The Royal Marsden NHS Foundation Trust.[1][4]

McDonald noted that the trial provides crucial prospective data for the oncology community. She emphasized that the results demonstrate "a significant improvement in progression-free survival without compromising quality of life," offering a clear biological rationale for the combined approach.[1][4]

Halting Local Progression

After a median follow-up period of 37.4 months, the clinical benefits of the radiation were stark. Patients in the radiotherapy arm experienced a median progression-free survival of 13.9 months, a five-month absolute improvement over the 8.9 months observed in the systemic-therapy-only group.[1][6]

That difference translates to a hazard ratio of 0.64, representing a 36 percent reduction in the risk of disease progression or death. The most profound effect was seen exactly where the radiation was aimed: the sites of the initial disease present at diagnosis.[6]

Progression at those original tumor locations occurred in just 13.0 percent of the patients who received consolidation radiotherapy. In contrast, 39.5 percent of the patients treated with systemic therapy alone saw their cancer resume growing at those initial sites within the first year.[1][6]

Dr. Dani Skirrow, a science engagement manager at Cancer Research UK, highlighted the practical value of that delay. "We now know that adding targeted radiotherapy to standard treatment helps keep cancer under control for longer, giving people precious time to carry on doing the things that matter to them with their loved ones," Skirrow said.[5]

The Survival Paradox

Despite the definitive success in halting local tumor growth, the aggressive intervention did not help patients live longer overall. The median overall survival was 31.0 months in the radiotherapy arm and 28.0 months in the control arm, yielding a hazard ratio of 0.99 that is not statistically significant.[4][6]

This survival paradox defines the limits of local therapy in metastatic cancer. While radiation successfully eradicates the visible tumors, microscopic disease circulating elsewhere in the body eventually progresses, dictating the patient's ultimate survival timeline regardless of how well the initial sites were controlled.[6]

Crucially, the addition of radiation did not subject patients to unmanageable side effects. A primary concern with combining radiation and systemic therapy is overlapping toxicity, particularly inflammation of the lungs or esophagus, but the trial data showed no such spike.[2]

The rate of grade 3 or higher adverse events was identical across both cohorts, sitting at 28.6 percent. Only six patients in the experimental arm experienced a severe adverse event that investigators considered possibly related to the radiotherapy, and patient-reported quality-of-life scores remained stable.[2]

For oncologists, the SARON results confirm that local consolidation is a powerful tool for disease control in oligometastatic lung cancer. The next clinical challenge will be identifying specific patient subgroups whose microscopic disease is indolent enough that this local control actually translates into a long-term survival cure.[6]